In this article, we are going to take a look at where Akebia Therapeutics Inc. (NASDAQ:AKBA) stands against other Thursday’s worst-performing stocks. Wall Street’s main indices edged lower on ...

Akebia Therapeutics, Inc. AKBA is a biopharmaceutical company. that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum ...

Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.

Akebia Therapeutics (AKBA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

And also on Monday, CEO and President John P. Butler purchased $11,567 worth of Akebia Therapeutics (AKBA), purchasing 1,000 shares at a cost of $11.57 a piece. Before this latest buy ...

Akebia Therapeutics (NASDAQ:AKBA) announced Thursday that it has regained full rights to sell its newly approved kidney disease therapy Vafseo (vadadustat) in the U.S. after its partner CSL Vifor ...